Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence
Status:
Withdrawn
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The objective of the present study is to evaluate the efficacy of topiramate (250mg/day)
versus placebo in decreasing aggression and reducing alcohol consumption in patients with
borderline personality disorder (BPD) and alcohol dependence (AD).